Company intelligence / Profile preview

Endorecherche, Inc.

Ownership: Private
Development stage: Phase 3

Overview

Endorecherche develops small molecule therapeutics targeting women’s health issues—especially menopause-related symptoms—and hormone-sensitive cancer prevention. Their work centers on novel administration methods for sex steroid precursors such as DHEA to maximize local benefits while minimizing systemic risks. They also supply active pharmaceutical ingredients like acolbifene. Clinical results are not detailed publicly but the company holds several patents for these approaches.

Therapeutic areas: Men's HealthOncologyEndocrinologyDermatologyNephrologyWomen's Health
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

acolbifene

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Endorecherche, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endorecherche, Inc..

Explore the full profile